PL3672639T3 - Produkt kombinowany inhibitora Bcl-2 i ibrutynibu do zastosowania w zapobieganiu i/lub leczeniu nowotworu złośliwego - Google Patents

Produkt kombinowany inhibitora Bcl-2 i ibrutynibu do zastosowania w zapobieganiu i/lub leczeniu nowotworu złośliwego

Info

Publication number
PL3672639T3
PL3672639T3 PL19844315T PL19844315T PL3672639T3 PL 3672639 T3 PL3672639 T3 PL 3672639T3 PL 19844315 T PL19844315 T PL 19844315T PL 19844315 T PL19844315 T PL 19844315T PL 3672639 T3 PL3672639 T3 PL 3672639T3
Authority
PL
Poland
Prior art keywords
ibrutinib
bcl
cancer
inhibitor
prevention
Prior art date
Application number
PL19844315T
Other languages
English (en)
Inventor
Dajun Yang
Yifan Zhai
Douglas Dong Fang
Guangfeng Wang
Guoqin ZHAI
Original Assignee
Ascentage Pharma (Suzhou) Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascentage Pharma (Suzhou) Co., Ltd. filed Critical Ascentage Pharma (Suzhou) Co., Ltd.
Publication of PL3672639T3 publication Critical patent/PL3672639T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL19844315T 2018-07-31 2019-07-30 Produkt kombinowany inhibitora Bcl-2 i ibrutynibu do zastosowania w zapobieganiu i/lub leczeniu nowotworu złośliwego PL3672639T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810867251 2018-07-31
PCT/CN2019/098252 WO2020024916A1 (en) 2018-07-31 2019-07-30 Combination product of bcl-2 inhibitor or bcl-2/bcl-xl dual inhibitor and btk inhibitor and use thereof in the prevention and/or treatment of diseases
EP19844315.2A EP3672639B1 (en) 2018-07-31 2019-07-30 Combination product of a bcl-2 inhibitor and ibrutinib for use in the prevention and/or treatment of cancer

Publications (1)

Publication Number Publication Date
PL3672639T3 true PL3672639T3 (pl) 2022-05-09

Family

ID=69232343

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19844315T PL3672639T3 (pl) 2018-07-31 2019-07-30 Produkt kombinowany inhibitora Bcl-2 i ibrutynibu do zastosowania w zapobieganiu i/lub leczeniu nowotworu złośliwego

Country Status (15)

Country Link
US (1) US11478470B2 (pl)
EP (1) EP3672639B1 (pl)
JP (1) JP7085635B2 (pl)
KR (1) KR20200138724A (pl)
CN (2) CN110772521A (pl)
AU (1) AU2019315487B2 (pl)
BR (1) BR112020019189A2 (pl)
CA (1) CA3094452C (pl)
EA (1) EA202091965A1 (pl)
GE (1) GEP20237508B (pl)
MX (1) MX2020009758A (pl)
PL (1) PL3672639T3 (pl)
TW (1) TWI758623B (pl)
UA (1) UA125199C2 (pl)
WO (1) WO2020024916A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554127B2 (en) 2018-07-31 2023-01-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CN110772639B (zh) 2018-07-31 2021-04-13 苏州亚盛药业有限公司 Bcl-2抑制剂与MDM2抑制剂的组合产品及其在预防和/或治疗疾病中的用途
TWI725488B (zh) 2018-07-31 2021-04-21 大陸商蘇州亞盛藥業有限公司 Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途
WO2021110097A1 (en) * 2019-12-03 2021-06-10 Ascentage Pharma (Suzhou) Co., Ltd. N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
US20230078120A1 (en) * 2020-05-04 2023-03-16 Ascentage Pharma (Suzhou) Co.,Ltd. Methods for Treating Coronavirus Infections
CN118161618A (zh) * 2020-06-18 2024-06-11 苏州亚盛药业有限公司 包含Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂的组合产品及其用途
CN115701997A (zh) * 2020-08-10 2023-02-14 江苏恒瑞医药股份有限公司 Btk抑制剂治疗疾病的用途
US20230301989A1 (en) * 2020-08-21 2023-09-28 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating systemic lupus erythematosus
CN114073703B (zh) * 2020-08-21 2022-12-30 苏州亚盛药业有限公司 用于治疗非酒精性脂肪肝炎的组合物和方法
JP2023550416A (ja) * 2020-11-20 2023-12-01 ベイジーン スウィッツァーランド ゲーエムベーハー Btk阻害剤を用いて全身性エリテマトーデスを治療する方法
CN114681458B (zh) * 2020-12-28 2023-07-18 苏州亚盛药业有限公司 治疗多发性硬化症的方法
IL308931A (en) * 2021-06-02 2024-01-01 Beigene Switzerland Gmbh Methods for treating malignant B cells using a Bcl-2 inhibitor
WO2023011488A1 (zh) * 2021-08-02 2023-02-09 苏州亚盛药业有限公司 一种药物组合及其用途
WO2023169357A1 (en) * 2022-03-07 2023-09-14 Ascentage Pharma (Suzhou) Co., Ltd. Methods for treating immune diseases
TW202339721A (zh) * 2022-03-31 2023-10-16 英屬開曼群島商百濟神州有限公司 Bcl-xL抑制劑
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
EP2061560A2 (en) 2006-09-05 2009-05-27 Abbott Laboratories Bcl inhibitors for treating platelet excess
WO2008070663A2 (en) 2006-12-04 2008-06-12 Abbott Laboratories Companion diagnostic assays for cancer therapy
PE20091180A1 (es) 2007-12-27 2009-08-26 Infinity Pharmaceuticals Inc Tratamientos terapeuticos contra el cancer
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
EP3666758A1 (en) 2008-12-05 2020-06-17 AbbVie Inc. Process for the preparation of a sulfonamide derivative
JP2012517241A (ja) 2009-02-11 2012-08-02 アボット・ラボラトリーズ Bcl−2ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物
DK2435432T6 (da) 2009-05-26 2023-12-18 Abbvie Ireland Unlimited Co Apoptose-inducerende midler til behandling af cancer og immune og autoimmune sygdomme
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
CA2811805A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
DK2642999T3 (en) 2010-11-23 2017-01-09 Abbvie Ireland Unlimited Co METHODS OF TREATMENT FOR USING selectivity-VE BCL-2 INHIBITORS
KR101923364B1 (ko) 2010-11-23 2018-11-30 애브비 인코포레이티드 아폽토시스­유도제의 염 및 결정형
JP5998152B2 (ja) 2011-01-25 2016-09-28 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Bcl−2/bcl−xl阻害剤およびそれを使用する治療方法
CA2897055C (en) * 2013-01-16 2021-04-20 The Regents Of The University Of Michigan Substituted 2-(trifluoromethylsulfonyl)phenylamino compounds and pharmaceutical compositions thereof as bcl-2/bcl-xl inhibitors and therapeutic methods using the same
US9925192B2 (en) 2014-02-28 2018-03-27 Merck Sharp & Dohme Corp. Method for treating cancer
AU2015247646B2 (en) 2014-04-17 2019-06-06 The Regents Of The University Of Michigan MDM2 inhibitors and therapeutic methods using the same
HUE056329T2 (hu) * 2014-08-11 2022-02-28 Acerta Pharma Bv BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
TW201717953A (zh) * 2015-08-03 2017-06-01 基利科學股份有限公司 用於治療癌症之組合療法
CN105061315B (zh) 2015-08-06 2017-10-24 大连理工大学 一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用
US20190060309A1 (en) 2015-08-28 2019-02-28 Novartis Ag Mdm2 inhibitors and combinations thereof
EP3569601B1 (en) * 2016-08-05 2022-06-22 The Regents of The University of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
US11554127B2 (en) 2018-07-31 2023-01-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
CN110772639B (zh) 2018-07-31 2021-04-13 苏州亚盛药业有限公司 Bcl-2抑制剂与MDM2抑制剂的组合产品及其在预防和/或治疗疾病中的用途
TWI725488B (zh) 2018-07-31 2021-04-21 大陸商蘇州亞盛藥業有限公司 Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途
AU2019385458A1 (en) 2018-11-23 2021-01-07 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and use thereof

Also Published As

Publication number Publication date
US11478470B2 (en) 2022-10-25
EP3672639A1 (en) 2020-07-01
EA202091965A1 (ru) 2021-05-14
GEP20237508B (en) 2023-05-25
JP2021523091A (ja) 2021-09-02
AU2019315487B2 (en) 2022-07-14
KR20200138724A (ko) 2020-12-10
UA125199C2 (uk) 2022-01-26
BR112020019189A2 (pt) 2021-02-09
TWI758623B (zh) 2022-03-21
WO2020024916A1 (en) 2020-02-06
TW202007396A (zh) 2020-02-16
AU2019315487A1 (en) 2020-10-01
CN114522167A (zh) 2022-05-24
CA3094452A1 (en) 2020-02-06
US20200222393A1 (en) 2020-07-16
MX2020009758A (es) 2020-10-08
CN110772521A (zh) 2020-02-11
JP7085635B2 (ja) 2022-06-16
CA3094452C (en) 2023-02-21
EP3672639A4 (en) 2020-09-30
EP3672639B1 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
PL3672639T3 (pl) Produkt kombinowany inhibitora Bcl-2 i ibrutynibu do zastosowania w zapobieganiu i/lub leczeniu nowotworu złośliwego
EP3672594A4 (en) COMBINATION PRODUCT OF BCL-2-INHIBITOR AND MDM2-INHIBITOR AND USE THEREOF FOR THE PREVENTION AND / OR TREATMENT OF DISEASES
EP3672595A4 (en) COMBINATION PRODUCT OF A BCL-2 INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND ASSOCIATED USE IN THE PREVENTION AND / OR TREATMENT OF DISEASES
IL268327A (en) A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases
HK1259545A1 (zh) 用於治療癌症的bcl-2抑制劑和mek抑制劑組合產品
IL266623A (en) A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer
EP3843751A4 (en) BCL-2/BCL-XL INHIBITOR AND CHEMOTHERAPEUTIC COMBINATION PRODUCT AND USE THEREOF FOR THE PREVENTION AND/OR TREATMENT OF DISEASE
IL281999A (en) YAP/TAZ-TEAD interaction inhibitors and their use in cancer therapy
IL280475A (en) A pharmaceutical composition for use in the treatment or prevention of a C5-related disease and a method for the treatment or prevention of a C5-related disease
IL265961A (en) Use of caspase-3 inhibitors and caspase-3 activators in the preparation of medical preparations for cancer treatment and wound healing
HK1257239A1 (zh) 預防和治療肥胖症的藥物及其用途
IL289758A (en) Proportin inhibitors for use in the prevention and treatment of kidney damage
IL283937A (en) Combined treatment with raf inhibitor and cdk4/6 inhibitor for use in cancer treatment
SG11202107720UA (en) Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
IL290656A (en) Lorbinectadine in the treatment of malignant mesothelioma
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
SI3969000T1 (sl) Bcl-2 inhibitorji za uporabo pri zdravljenju z Bcl-2 posredovanega raka, ki nosi mutacijo Gly101Val
IL268860A (en) Granzyme B inhibitor preparations and methods for preventing and/or treating blistered and/or peeling skin
HK1246205A1 (zh) 在預防和/或治療皮膚損傷中使用的至少一種蛋白酶抑制劑和至少一種活性成分的組合
HUP1900281A1 (hu) Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra
PT3969000T (pt) Inibidores de bcl-2 para utilização no tratamento de um cancro mediado por bcl-2 que transporta a mutação gly101val
PL3813843T3 (pl) Kompozycja do stosowania w zapobieganiu i/lub leczeniu chorób układu kostno-stawowego
EP3829564C0 (en) CURCUMIN AND HOMOTAURINE FOR USE IN THE PREVENTION OR TREATMENT OF FORMS OF COGNITIVE DECLINE
AU2019902712A0 (en) Inhibitors and use thereof in cancer treatment
IL286326A (en) Azetidobenzodiazepine dimers and conjugates containing them for use in cancer therapy